Your browser doesn't support javascript.
loading
Steady-state versus chemotherapy-based hematopoietic cell mobilization after anti-CD38-based induction therapy in newly diagnosed multiple myeloma.
Teipel, Raphael; Rieprecht, Susanne; Trautmann-Grill, Karolin; Röllig, Christoph; Klötzer, Christina; Zimmer, Kristin; Rathaj, Grit; Bach, Enrica; Brückner, Mandy; Heyn, Simone; Wang, Song-Yau; Jentzsch, Madlen; Schwind, Sebastian; Kretschmann, Theresa; Egger-Heidrich, Katharina; Remane, Yvonne; Franke, Georg-Nikolaus; von Bonin, Malte; Bornhäuser, Martin; Platzbecker, Uwe; Hölig, Kristina; Merz, Maximilian; Vucinic, Vladan.
Afiliación
  • Teipel R; Department of Internal Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany.
  • Rieprecht S; Department of Hematology, Cellular Therapy, Hemostaseology, and Infectious Diseases, University Leipzig Medical Center, Leipzig, Germany.
  • Trautmann-Grill K; Pharmacy, University Leipzig Medical Center, Leipzig, Germany.
  • Röllig C; Department of Internal Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany.
  • Klötzer C; Department of Internal Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany.
  • Zimmer K; Department of Hematology, Cellular Therapy, Hemostaseology, and Infectious Diseases, University Leipzig Medical Center, Leipzig, Germany.
  • Rathaj G; Department of Internal Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany.
  • Bach E; Department of Internal Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany.
  • Brückner M; Department of Hematology, Cellular Therapy, Hemostaseology, and Infectious Diseases, University Leipzig Medical Center, Leipzig, Germany.
  • Heyn S; Department of Hematology, Cellular Therapy, Hemostaseology, and Infectious Diseases, University Leipzig Medical Center, Leipzig, Germany.
  • Wang SY; Department of Hematology, Cellular Therapy, Hemostaseology, and Infectious Diseases, University Leipzig Medical Center, Leipzig, Germany.
  • Jentzsch M; Department of Hematology, Cellular Therapy, Hemostaseology, and Infectious Diseases, University Leipzig Medical Center, Leipzig, Germany.
  • Schwind S; Department of Hematology, Cellular Therapy, Hemostaseology, and Infectious Diseases, University Leipzig Medical Center, Leipzig, Germany.
  • Egger-Heidrich K; Department of Internal Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany.
  • Remane Y; Department of Internal Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany.
  • Franke GN; Pharmacy, University Leipzig Medical Center, Leipzig, Germany.
  • von Bonin M; Department of Hematology, Cellular Therapy, Hemostaseology, and Infectious Diseases, University Leipzig Medical Center, Leipzig, Germany.
  • Bornhäuser M; Department of Internal Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany.
  • Platzbecker U; Department of Internal Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany.
  • Hölig K; National Center for Tumor Disease (NCT), Dresden, Germany.
  • Merz M; Department of Hematology, Cellular Therapy, Hemostaseology, and Infectious Diseases, University Leipzig Medical Center, Leipzig, Germany.
  • Vucinic V; Department of Internal Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany.
Transfusion ; 63(11): 2131-2139, 2023 11.
Article en En | MEDLINE | ID: mdl-37850414
BACKGROUND: The incorporation of anti-CD38 monoclonal antibodies (mAb) in induction regimens of newly diagnosed transplant-eligible multiple myeloma (MM) patients has been established as a new standard. However, the optimal strategy of stem cell mobilization in this context is not yet clear. STUDY DESIGN AND METHODS: From May 2020 till September 2022, we retrospectively reviewed patients receiving anti-CD38 mAb-based induction therapy followed by stem cell mobilization either in a steady-state protocol (SSM) using 10 µg/kg granulocyte colony-stimulating factor (G-CSF) for 5 days or in a chemotherapy-based protocol (CM) using 1-4 g/m2 cyclophosphamide and G-CSF. RESULTS: Overall, 85 patients (median age 61 years) were included in the analysis. In total, 90 mobilization attempts were performed, 42 with SSM and 48 with CM. There was no significant difference in the median concentration of CD34+ cells in peripheral blood (PB) prior to apheresis between SSM and CM (61/µL vs. 55.4/µL; p = .60). Cumulative CD34+ yields did not differ between the groups with median of 6.68 and 6.75 × 106 /kg body weight, respectively (p = .35). The target yield (≥4 × 106 CD34+ cells/kg body weight) was reached in 88% (CM) and 86% (SSM), with a high proportion even after a single apheresis session (76% vs. 75%). Plerixafor was found to be more frequently used in SSM (52%) than in CM (23%; p < .01). A total of 83 patients underwent autologous transplantation and all were engrafted. CONCLUSIONS: Stem cell collection in patients undergoing anti-CD38-based induction therapy is feasible with either CM or SSM, although SSM more frequently requires plerixafor.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trasplante de Células Madre Hematopoyéticas / Compuestos Heterocíclicos / Mieloma Múltiple / Antineoplásicos Límite: Humans / Middle aged Idioma: En Revista: Transfusion Año: 2023 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trasplante de Células Madre Hematopoyéticas / Compuestos Heterocíclicos / Mieloma Múltiple / Antineoplásicos Límite: Humans / Middle aged Idioma: En Revista: Transfusion Año: 2023 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Estados Unidos